Positron Corporation Wins Innovation Award in PET-CT Category from Medical Device Network’s Excellence Awards 2025
Positron Corporation (OTC: POSC) has been awarded the Innovation Award in the PET-CT Imaging category at the 2025 Medical Device Network Excellence Awards. The company's PET-CT 64 Slice system stands out as the most cost-effective PET-CT system in the US, making advanced hybrid imaging more accessible to smaller clinics and community hospitals.
The system offers significant advantages including enhanced workflow efficiency with capability to perform up to 20+ exams daily, flexible rental packages, and comprehensive clinical applications across cardiac, oncology, and neurology imaging. Positron plans to launch its advanced Affinity 4D PET-CT system in Q4 2025, featuring LYSO crystal technology, AI-enhanced motion monitoring, and improved dose reduction techniques.
Positron Corporation (OTC: POSC) ha ricevuto il Innovation Award nella categoria PET-CT Imaging ai Medical Device Network Excellence Awards 2025. Il sistema PET-CT a 64 Slice dell'azienda si distingue come il più conveniente sistema PET-CT negli Stati Uniti, rendendo l'imaging ibrido avanzato più accessibile a cliniche più piccole e ospedali comunitari.
Il sistema offre vantaggi significativi tra cui efficienza del flusso di lavoro potenziata con capacità di eseguire fino a oltre 20 esami al giorno, pacchetti di noleggio flessibili e applicazioni cliniche complete in cardiologia, oncologia e neurologia. Positron prevede di lanciare il suo avanzato sistema Affinity 4D PET-CT nel Q4 2025, con tecnologia a cristalli LYSO, monitoraggio del movimento potenziato dall'IA e tecniche migliorate di riduzione della dose.
Positron Corporation (OTC: POSC) ha sido galardonada con el Innovation Award en la categoría PET-CT Imaging en los Medical Device Network Excellence Awards 2025. El sistema PET-CT de 64 slices de la empresa destaca como el más rentable sistema PET-CT en EE. UU., haciendo que la imagenología híbrida avanzada sea más accesible para clínicas más pequeñas y hospitales comunitarios.
El sistema ofrece ventajas significativas, incluyendo una mayor eficiencia del flujo de trabajo con capacidad para realizar hasta 20+ exámenes diarios, planes de alquiler flexibles y amplias aplicaciones clínicas en cardiología, oncología y neurología. Positron planea lanzar su avanzado sistema Affinity 4D PET-CT en el Q4 de 2025, que contará con tecnología de cristal LYSO, monitoreo de movimiento impulsado por IA y técnicas mejoradas de reducción de dosis.
Positron Corporation (OTC: POSC)는 2025년 Medical Device Network Excellence Awards에서 PET-CT Imaging 부문 Innovation Award를 수상했습니다. 회사의 64슬라이스 PET-CT 시스템은 미국에서 가장 비용 효율적인 PET-CT 시스템으로 돋보이며, 고급 하이브리드 영상이 소형 클리닉과 커뮤니티 병원에서도 더 쉽게 이용될 수 있도록 해줍니다.
이 시스템은 작업 흐름의 효율성 향상과 함께 하루에 최대 20건 이상 검사 가능, 유연한 렌탈 패키지, 심혈관, 종양학, 신경학 영상에 걸친 포괄적 임상 활용 등 중요한 이점을 제공합니다. Positron은 2025년 4분기에 고급 Affinity 4D PET-CT 시스템의 출시를 계획하고 있으며, LYSO 결정 기술, AI 기반 모션 모니터링, 비 dose 감소 기술이 향상됩니다.
Positron Corporation (OTC: POSC) a reçu le Innovation Award dans la catégorie PET-CT Imaging lors des Medical Device Network Excellence Awards 2025. Le système PET-CT à 64 coupes de l'entreprise se démarque comme le système PET-CT le plus rentable des États-Unis, rendant l'imagerie hybride avancée plus accessible aux cliniques plus petites et aux hôpitaux communautaires.
Le système offre des avantages significatifs, notamment une efficacité du flux de travail améliorée avec la capacité d'effectuer jusqu'à 20 examens par jour, des packages de location flexibles et des applications cliniques complètes en cardiologie, oncologie et neurologie. Positron prévoit le lancement de son système avancé Affinity 4D PET-CT en Q4 2025, équipé de la technologie de cristaux LYSO, de la surveillance des mouvements pilotée par IA et de techniques améliorées de réduction de dose.
Positron Corporation (OTC: POSC) wurde bei den Medical Device Network Excellence Awards 2025 mit dem Innovation Award in der Kategorie PET-CT Imaging ausgezeichnet. Das 64-Schichten-PET-CT-System des Unternehmens zeichnet sich als kostengünstigstes PET-CT-System in den USA aus und macht fortschrittliche Hybridbildgebung zugänglicher für kleineren Kliniken und kommunale Krankenhäuser.
Das System bietet wesentliche Vorteile, darunter eine verbesserte Arbeitsabläufe mit der Fähigkeit, bis zu 20+ Untersuchungen pro Tag durchzuführen, flexible Mietpakete und umfassende klinische Anwendungen in Kardio-, Onko- und Neurologie-Bildgebung. Positron plant die Einführung seines fortschrittlichen Affinity 4D PET-CT-Systems im Q4 2025, das LYSO-Kristalltechnologie, KI-gestützte Bewegungsüberwachung und verbesserte Dosisreduzierungstechniken umfasst.
Positron Corporation (OTC: POSC) حاصلة على جائزة الابتكار في فئة PET-CT Imaging خلال جوائز Medical Device Network Excellence 2025. يبرز نظام PET-CT المكوّن من 64 شريحة للشركة كـ أكثر أنظمة PET-CT كفاءة من حيث التكلفة في الولايات المتحدة، مما يجعل التصوير الهجين المتقدم أكثر وصولاً للعيادات الصغيرة والمستشفيات المجتمعية.
يقدّم النظام مزايا كبيرة بما في ذلك كفاءة سير العمل المحسّنة مع قدرة إجراء حتى 20 فحصًا يوميًا، وخطط إيجار مرنة وتطبيقات سريرية شاملة في تصوير القلب، والأورام، والأعصاب. وتخطط بوزيترون لإطلاق نظامها المتقدم Affinity 4D PET-CT في الربع الرابع من 2025، مع تقنية بلورة LYSO، ومراقبة حركة مدعومة بالذكاء الاصطناعي، وتقنيات تقليل جرعة محسّنة.
Positron Corporation (OTC: POSC) 荣获2025年 Medical Device Network Excellence Awards 的 PET-CT Imaging 类别创新奖。该公司64层PET-CT系统被誉为 美国最具性价比的PET-CT系统，使先进的混合成像对较小诊所和社区医院也更易获得。
该系统具有显著优势，包括 工作流效率提升，每天可进行多达 20 次以上的检查、灵活的租赁方案，以及心脏病学、肿瘤学和神经学成像等广泛临床应用。Positron 计划在 2025 年第四季度推出其先进的 Affinity 4D PET-CT 系统，具备 LYSO 晶体技术、AI 支持的运动监控以及改进的剂量降低技术。
- Most cost-effective PET-CT system in the US market
- High operational efficiency with capacity for 20+ exams per day
- Flexible rental and service options reducing upfront investment needs
- Versatile clinical applications covering cardiac, oncology, and neurology imaging
- New Affinity 4D PET-CT system launching in Q4 2025 with advanced features
- None.
Buffalo, NY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced that it has won the Innovation Award in the PET-CT Imaging category in the 2025 Medical Device Network Excellence Awards for making a substantial impact on the evolution of PET-CT imaging technology. The company’s latest PET-CT systems have introduced significant advancements in affordability, workflow, and clinical application.
The Medical Device Network Excellence Awards honor the most significant achievements and innovations in the global medical devices industry. Powered by GlobalData’s business intelligence, the Awards recognize the people and companies leading positive change and shaping the future of the industry.
Positron won the award for making hybrid molecular imaging more accessible, efficient, and clinically versatile for healthcare providers.
Expanding access through affordability and compact design
One of the most persistent challenges in the adoption of PET-CT imaging has been the high cost and substantial space requirements of traditional systems. Positron has addressed these barriers by developing PET-CT solutions that are economically accessible and physically adaptable to a wider range of healthcare environments. Positron’s PET-CT 64 Slice stands out as the most cost-effective PET-CT system currently available in the US, offering a lower price point that enables smaller clinics and community hospitals to consider advanced hybrid imaging for the first time.
The affordability is further supported by flexible rental and service options, which reduce the need for significant upfront investment. Positron offers all-inclusive rental packages, which cover not only the scanner but also clinical, technical, and training services, making it feasible for facilities with limited capital resources to implement PET-CT technology.
Driving workflow efficiency and operational performance
Operational efficiency is a critical factor for imaging providers, especially as patient volumes increase and healthcare systems seek to maximize throughput without sacrificing quality. Positron’s PET-CT systems are engineered to streamline workflow at every stage of the imaging process. The integration of CT attenuation correction, for instance, not only improves image quality but also accelerates scan times, enabling facilities to perform up to 20 or more exams per day – substantially higher than the throughput of standalone PET systems.
Enhancing clinical versatility and diagnostic confidence
Modern healthcare increasingly demands imaging platforms that can address a broad spectrum of clinical needs. Positron’s PET-CT systems are designed to support advanced cardiac, oncology, and neurology imaging within a single, versatile platform. Positron’s PET-CT is optimized for myocardial perfusion imaging — a critical tool in the assessment of coronary artery disease and microvascular dysfunction — but also offers high sensitivity and specificity for tumor detection and neurological evaluation.
Positron’s commitment to ongoing innovation is evident in its development pipeline. The forthcoming Affinity 4D PET-CT system, expected to be launched in Q4 2025, will introduce further advances such as LYSO crystal technology for enhanced image clarity, AI-enhanced motion monitoring, and advanced dose reduction techniques. This sustained focus on product development ensures that Positron’s systems remain responsive to evolving clinical requirements and continue to set new standards in hybrid imaging.
“Positron’s unmatched combination of technology, service, and economics offers practices the best value and a clear path to long-term sustainability and growth”, added Mr. Abdullah.
Link to the full article:
About Positron Corporation
Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America.
Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.
Positron's PET and PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine.
Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.
Please visit the Company’s website at: www.positron.com
Forward-Looking Statements
This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future.
FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact: investor@positron.com
Investor Relations Contact:
Skyline Corporate Communications Group, LLC
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
info@skylineccg.com
FAQ
What award did Positron Corporation (POSC) win in 2025?
What makes Positron's PET-CT 64 Slice system unique in the market?
When will Positron (POSC) launch its new Affinity 4D PET-CT system?
How does Positron's rental package system work for healthcare facilities?
What clinical applications does Positron's PET-CT system support?
